Accessibility StatementSkip Navigation Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Skye To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Skye between November 4, 2024 and October 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330Â (Ext. 1310). [You may also click here for additional information] NEW YORK, Nov. 21 ...

诉讼核心信息 - 谢尔律师事务所提醒投资者注意针对Skye Bioscience公司的集体诉讼案，指控其违反《1934年证券交易法》第10(b)和20(a)条以及美国证券交易委员会制定的10b-5规则 [1] - 诉讼指控公司在2024年11月4日至2025年10月3日期间发布了虚假和误导性陈述 [2][4] 指控内容 - 公司的主要候选药物nimacimab的实际疗效低于公司声称的效果 [4] - 公司夸大了其商业和临床前景，导致其在整个集体诉讼期间的公开陈述存在虚假和重大误导性 [4] - 当市场了解到Skye公司的真实情况后，投资者遭受了损失 [4]

New York, New York--(Newsfile Corp. - November 20, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 16, 2026.SO WHAT: If you purchased Skye securities during the C ...

集体诉讼公告 - Rosen Law Firm宣布代表在2024年11月4日至2025年10月3日期间购买Skye Bioscience Inc (NASDAQ: SKYE) 证券的购买者提起集体诉讼 [1] - 诉讼指控被告在整个集体诉讼期间就公司业务、运营和前景做出重大虚假和误导性陈述 [5] - 具体指控包括nimacimab的疗效不如被告引导投资者所相信的那样好 其临床、监管和商业前景被夸大 导致投资者在公司真实细节进入市场后遭受损失 [5] 诉讼参与信息 - 潜在参与者可通过访问特定网站、拨打免费电话或发送邮件联系Phillip Kim以加入集体诉讼 [3][6] - 希望担任首席原告的投资者必须在2026年1月16日前向法院提出动议 [1][3] - 在集体认证之前 投资者未被律师代表 可以选择自己的律师或保持缺席集体成员身份 [7] 律师事务所背景 - Rosen Law Firm是一家全球投资者权益律师事务所 专注于证券集体诉讼和股东衍生诉讼 [4] - 该事务所曾达成针对中国公司的史上最大证券集体诉讼和解 并因2017年证券集体诉讼和解数量被ISS Securities Class Action Services排名第一 [4] - 自2013年以来每年排名前四 为投资者追回数亿美元 其中2019年单独为投资者获得超过4.38亿美元 [4]

文章核心观点 - 律师事务所Bragar Eagel & Squire, P C宣布代表Skye Bioscience Inc和Perrigo Company plc的股东对两家公司提起集体诉讼 [1] Skye Bioscience Inc (SKYE) 诉讼摘要 - 诉讼指控公司在2024年11月4日至2025年10月3日期间就业务、运营和前景做出重大虚假和误导性陈述 [7] - 具体指控包括未披露其药物nimacimab的实际疗效低于公司向投资者传达的水平以及该药物的临床、监管和商业前景被夸大 [7] - 2025年10月6日公司公布nimacimab的二期临床试验顶线数据显示其单药治疗组未达到与安慰剂相比减轻体重的主要终点且药物暴露量低于预期 [7] - 此消息导致公司股价当日下跌2.85美元跌幅达60%收于每股1.90美元 [7] Perrigo Company plc (PRGO) 诉讼摘要 - 诉讼指控公司在2023年2月27日至2025年11月4日期间未能披露多项关键信息 [3] - 具体指控包括未披露从雀巢收购的婴儿配方奶粉业务存在维护、运营改进和维修方面的投资不足问题以及需要投入远超公司对外宣称的预估成本来进行补救 [3] - 指控还指出该婴儿配方奶粉业务的生产设施存在重大缺陷导致公司收益和现金流等财务结果被高估 [3] - 2025年11月5日公司公布令人失望的第三季度业绩并大幅下调2025财年展望主要归因于婴儿配方奶粉行业动态同时宣布启动对该业务的战略审查并重新评估此前宣布的2.4亿美元投资 [4] - 此消息导致公司股价当日下跌5.09美元跌幅达25.2%收于每股15.10美元 [4]

Nov 18, 2025 2:54 PM Eastern Standard Time The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit With the Schall Law Firm Share LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights ...

SAN DIEGO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Skye Bioscience, Inc. (NASDAQ: SKYE) securities between November 4, 2024 and October 3, 2025. Skye is a clinical stage biopharmaceutical company that focuses on developing molecules that modulate G protein-coupled receptors (“GPCRs”) to treat obesity, overweight, and metabolic diseases. The Company’s lead product candidate is nimacimab. Fo ...

公司诉讼事件 - Rosen Law Firm宣布对Skye Bioscience, Inc (NASDAQ: SKYE) 提起集体诉讼，代表在2024年11月4日至2025年10月3日期间购买或收购该公司证券的投资者 [1] - 诉讼指控公司在整个集体诉讼期间就业务、运营和前景做出重大虚假和误导性陈述 [3] - 具体指控包括：公司主要候选药物nimacimab的实际疗效低于公司向投资者传达的水平，其临床、监管和商业前景被夸大 [3] 公司业务背景 - Skye Bioscience, Inc 是一家临床阶段生物制药公司 [1] - 诉讼声称，当真实情况进入市场后，投资者遭受了损失 [3] 律师事务所信息 - Rosen Law Firm是一家全球投资者权益律师事务所，专注于股东权利诉讼 [6] - 该律所自成立以来已为股东追回超过10亿美元（$1 billion）的资金 [6]

NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Skye Bioscience, Inc. (“Skye” or “the Company”) (NASDAQ: SKYE) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Skye secu ...

ATLANTA, Nov. 18, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Skye Bioscience, Inc. ("Skye" or the "Company") (NASDAQ: SKYE). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose key facts, including allegations that:  (1) nimacimab was less effective than Defendants had led investors to believe; (2) accordingly, nimacimab's clinical, regulatory, and commercial prospects were overstated; and (3) as a result, D ...